Phospholipid transfer protein (PLTP) is a key lipid transport protein involved in the modulation of high-density lipoprotein (HDL) metabolism, facilitating the transfer of phospholipids, vitamin E, and other lipophilic molecules between lipoproteins. It plays a critical role in maintaining lipid homeostasis, HDL remodeling, and reverse cholesterol transport, a process crucial for preventing atherosclerosis. Dysregulation of PLTP activity has been linked to cardiovascular diseases, metabolic syndrome, and neurodegenerative disorders.
PLTP-specific antibodies are essential tools for studying its expression, structure, and function in both physiological and pathological contexts. These antibodies enable the detection and quantification of PLTP in biological samples using techniques like Western blotting, ELISA, and immunohistochemistry. Researchers also use them to investigate PLTP’s interaction with lipoproteins, cell receptors, and regulatory proteins.
Monoclonal and polyclonal PLTP antibodies have been developed, often targeting epitopes in its N-terminal or C-terminal domains. Their applications extend to preclinical studies, such as evaluating PLTP inhibition as a therapeutic strategy for atherosclerosis or exploring its role in inflammation. However, challenges remain in ensuring antibody specificity due to PLTP’s structural homology with other lipid-binding proteins. Continued development of high-affinity PLTP antibodies is critical for advancing research on lipid metabolism disorders and potential treatments.